Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants

Pediatrics

Volumn 117, Issue 4, 2006, Pages 1243-1252

  Uko, Smart ^a   Soghier, Lamia M ^a,b   Vega, Melissa ^a   Marsh, Jeremy ^a   Reinersman, Gerald T ^a   Herring, Lucille ^a   Dave, Viral A ^a   Nafday, Suhas ^a   Brion, Luc P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Candida albicans; Candida lusitaniae; Candida parapsilosis; Extremely low birth weight; Fluconazole; Invasive fungal infection; Logistic regression analysis; Preterm; Prophylaxis; Very low birth weight

Indexed keywords

AMPHOTERICIN; ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; FLUCONAZOLE; ANTIFUNGAL AGENT;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; EXTREMELY LOW BIRTH WEIGHT; FEMALE; FUNGAL COLONIZATION; HUMAN; INFANT; INFANT MORTALITY; INFECTION CONTROL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; MYCOSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; SHORT COURSE THERAPY; TREATMENT DURATION; VERY LOW BIRTH WEIGHT; ANTIBIOTIC PROPHYLAXIS; CANDIDIASIS; ECONOMICS; HEALTH CARE COST; MORTALITY; NEWBORN; PREMATURITY; SURVIVAL RATE;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CANDIDIASIS; FLUCONAZOLE; HEALTH CARE COSTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; MYCOSES; SURVIVAL RATE;

EID: 33646348473     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-1969     Document Type: Article

References (59)

1. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J. 2000;19:319-324
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291
3. Karlowicz MG, Rowen JL, Barnes-Eley ML, et al. The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study. Pediatr Res. 2002;51:301A
4. Kaufman D. Fungal infection in the very low birthweight infant. Curr Opin Infect Dis. 2004;17:253-259
5. Benjamin DK, DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark RH. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics. 2003;112:543-547
6. Feja KN, Wu F, Roberts K, et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr. 2005;147:156-161
7. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996;129:63-71
8. Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics. 2002;109:34-39
9. Rønnestad A, Abrahamsen TG, Medbø S, et al. Late-onset septicemia in a Norwegian national cohort of extremely premature infants receiving very early full human milk feeding. Pediatrics. 2005;115(3). Available at: www.pediatrics.org/cgi/content/full/115/3/e269
10. International Neonatal Network. The CRIB (Clinical Risk Index for Babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. Lancet. 1993;342:193-198
11. Cotton CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. Center differences in candidemia among extremely low birthweight (ELBW) infants: influence of antibiotic practices. PAS. 2005;57:644
12. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004;(3):CD004291
13. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev. 2002;(2):CD000026
14. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2004;(1):CD003850
15. Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect. 2004;10(suppl 1):86-95
16. Vanden Bossche H, Marichal P, Gorrens J, et al. Biochemical approaches to selective antifungal activity: focus on azole antifungals. Mycoses. 1989;32(suppl 1):35-52
17. Trzaskos JM, Henry MJ. Comparative effects of the azole-based fungicide flusilazole on yeast and mammalian lanosterol 14α-methyl demethylase. Antimicrob Agents Chemother. 1989;33:1228-1231
18. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-225
19. Burwell LA, Kaufman D, Stoll BJ, Tuboku-Metzger J, Fridkin SK. Prevention of neonatal candidemia in the United States: description of current antifungal prophylaxis practices of neonatologists, 2004. PAS. 2005;57:646
20. Young TE, Mangum B. Neofax. 16th ed. Raleigh, NC: Acorn Publishing; 2003
21. Benjamin DK, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112:634-640
22. Austin NC, Darlow B. Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev. 2004;(1):CD003478
23. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics. 2001;107:293-298
24. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-1666
25. Cabrera C, Frank M, Carter D, Bhatia J. Fluconazole prophylaxis against systemic candidiasis after colonization: a randomized, double-blinded study. J Perinatol. 2002;22:604
26. Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics. 2001;107:404-406
27. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr. 2005;147:172-179
28. Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr. 2005;147:166-171
29. Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr. 2005;147:162-165
30. Roilides E, Farmaki E, Evdoridou J, et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis. 2004;23:745-750
31. Chong E, Kazzi NJ. End organ damage in Candida albicans and Candida parapsilosis infections among very low birth weight infants. PAS. 2005;57:648
32. Arendrup M, Horn T, Frimodt-Moller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection. 2002;30:286-291
33. Huan YC, Li CC, Lin TY, et al. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J. 1998;17:819
34. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother. 1999;43:1955-1960
35. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-996
36. Katz HI. Drugs interactions of the newer oral antifungal agents. Br J Dermatol. 1999;141(suppl 56):26-32
37. Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother. 2002;50:231-240
38. Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis. 2001;33:1069-1075
39. Chryssanthou E, Cherif H, Petrini B, Kalin M, Bjorkholm M. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis. 2004;36:855-859
40. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519-1527
41. Sarvikivi E, Lyytikainen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol. 2005;43:2729-2735
42. Marr KA, Lyons CN, Rustad T, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother. 1998;42:2584-2589
43. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhäuser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother. 1998;42:3065-3072
44. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49:668-679
45. Chen CG, Yang YL, Shih HI, Su SL, Lo HJ. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother. 2004,48:4505-4512
46. Kamai Y, Maebashi K, Kudoh M, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol. 2004;48:937-943
47. Liu TT, Lee RE, Barker KS, et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother. 2005;49:2226-2236
48. Roemer T, Jiang B, Davison J, et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol. 2003;50:167-181
49. Hooshdaran MZ, Barker KS, Hilliard GM, Kusch H, Morschhauser J, Rogers PD. Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother. 2004;48:2733-2735
50. Hooshdaran MZ, Hilliard GM, Rogers PD. Application of proteomic analysis to the study of azole antifungal resistance in Candida albicans. Methods Mol Med. 2005;118:57-70
51. Bruneau JM, Maillet I, Tagat E, et al. Drug induced proteome changes in Candida albicans: comparison of the effect of (1,3)glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics. 2003;3:325-336
52. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1997;41:1482-1487
53. Redding SW, Kirkpatrick WR, Saville S, et al. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol. 2003;41:619-622
54. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005;43:4434-4440
55. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr. 2005;147:135-141
56. Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993;54:269-277
57. 14C]fluconazole in humans. Drug Metab Dispos. 1991;19:764-767
58. Frattarelli DA, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs. 2004;64:949-968
59. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247:625-634